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Abstract. Cisplatin-pemetrexed is a frequently adopted 
first‑line treatment for patients with advanced non‑small cell 
lung cancer (NSCLC) ineligible for biological therapy, notwith-
standing its limited efficacy. In the present study, the RAL cell 
line, an epidermal growth factor receptor (EGFR)‑wild‑type, 
p53- and KRAS‑mutated model of NSCLC, was used to inves-
tigate novel biomarkers of resistance to this treatment. Cells 
were analyzed 96 h (96 h‑post wo) and 21 days (21 days‑post 
wo) after the combined treatment washout. Following an initial 
moderate sensitivity to the treatment, the cell growth prolifera-
tive capability had fully recovered. Gene expression analysis 
of the resistant surviving cells revealed a significant upregu-
lation of CDKN1A expression in the cells at 96‑h post‑wo 
and, although to a lesser extent, in the cells at 21 days‑post 
wo, accompanied by an enrichment of acetylated histone H3 
in its promoter region. CDKN1A was also upregulated at the 
protein level, being mainly detected in the cytoplasm of the 
cells at 96 h‑post wo. A marked increase in the number of 
apoptotic cells, together with a significant G1 phase block, 
were observed at 96‑h post wo in the cells in which CDKN1A 
was knocked down, suggesting its involvement in the modula-
tion of the response of RAL cells to the drug combination. On 
the whole, these data suggest that CDKN1A plays a role in the 
response to the cisplatin‑pemetrexed combination in advanced 
KRAS‑mutated NSCLC, thus suggesting that it may be used as 
a promising predictive marker.
Introduction
Lung cancer is the leading cause of cancer‑associated 
mortality worldwide (1‑3). More than 80% of patients with 
lung cancer suffer from non‑small cell lung cancer (NSCLC), 
and the majority have advanced disease at diagnosis with a 
poor prognosis (4).
Adenocarcinoma is the most common subtype of NSCLC. 
In addition to epidermal growth factor receptor (EGFR) 
mutations that occur in approximately 50% of patients, the 
oncogene KRAS, responsible for tumor formation, and the 
tumor suppressor gene TP53, implicated in cell cycle regulation, 
cell proliferation and apoptosis, are also frequently mutated in 
this type of tumor, with EGFR and KRAS mutations gener-
ally mutually exclusive (1). The role of such mutations in the 
selection of the anticancer treatment is still under debate, even 
though it appears that they may be associated with differential 
sensitivity patterns to currently available therapies (5,6).
Specific targeted therapies are available for patients with 
advanced disease harboring EGFR mutations or anaplastic 
lymphoma kinase (ALK) translocation, and immunotherapy 
has also been increasingly adopted on the basis of the 
programmed death protein 1 (PD‑1) level. It is still not clear 
how the remaining mutations could drive the selection of anti-
cancer treatment. The American Society of Clinical Oncology 
and National Comprehensive Cancer Network (NCCN) 
recommends a combination of two cytotoxic drugs for the 
first‑line therapy of patients who are not eligible for biological 
treatment (7). The antifolate drug, pemetrexed, is frequently 
used in combination with cisplatin, since an improved overall 
survival has been observed in patients treated with this combi-
nation compared to those undergoing the cisplatin‑gemcitabine 
regimen (8). However, acquired drug resistance mechanisms 
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are common and compromise the efficacy of chemotherapy 
for lung cancer (8‑11). The mechanism of action of cisplatin 
relies on the induction of DNA damage (12), resulting in cell 
cycle arrest and subsequent apoptosis. Neoplastic cells activate 
several genes involved in DNA damage repair to withstand 
platinum‑based chemotherapy. Among these, cyclin‑dependent 
kinase inhibitor 1A (CDKN1A) plays a central role in cell cycle 
progression, regulating both G1/S and G2/M checkpoints. 
Upon DNA damage, CDKN1A is transiently recruited to target 
sites to facilitate their repair. However, CDKN1A activity is 
dependent on the p53 status. In fact, upon p53 loss‑of‑function 
mutation, CDKN1A overexpression drives cells to acquire a 
more aggressive phenotype that is capable of escaping cell 
block, senescence and apoptosis (13).
The aim of the present study was to identify novel poten-
tial biomarkers involved in the onset of resistance to the 
cisplatin‑pemetrexed combination in an EGFR‑wild type (wt) 
NSCLC cell line (RAL) harboring KRAS and TP53 mutations.
Materials and methods
Cells and cell culture. The NSCLC cell line, RAL, is 
derived from a metastatic lesion of lung adenocarcinoma of 
a 52‑year‑old female previously treated with cisplatin (14). 
The identity of the patient was irreversibly anonymized prior 
to specimen processing. The cell line is characterized by 
the following: EGFR‑wt, KRAS mutation at exon 1 (p.G12C, 
missense, not functional, deleterious), TP53 mutation at 
exon 7 (p.G244C, missense, not functional, deleterious) and 
no ALK rearrangement. The cells were grown in Dulbecco's 
modified Eagle's medium/HAM F12 (1:1) supplemented with 
10% fetal bovine serum, 2 mM of L‑glutamine (EuroClone) 
and 10 µg/ml of insulin (Sigma‑Aldrich; Merck KGaA) in a 
humidified atmosphere with 5% CO2 at 37˚C. The population 
doubling time was 65 h, as previously described (14).
Chemosensitivity assay. Cisplatin (Ebewe Pharma‑Sandoz) 
and pemetrexed (Eli Lilly Italia Spa) were tested at plasma 
peak concentrations (10 and 320.5 µM, respectively). Cell 
viability was assessed by MTS assay according to the manu-
facturer's protocol (CellTiter 96® AQueous One Solution Cell 
Proliferation assay, Promega Corp.). Experiments were run 
in octuplicate and each experiment was repeated 3 times. 
To ensure that the exposure time was compatible with the 
half‑life of the drugs administered as in a clinical setting, 
the cells were treated with pemetrexed or cisplatin alone and 
washed out with drug‑free medium after 3 and 6 h of exposure, 
respectively, followed by up to 96 h of recovery, as previously 
described (15). For the combination treatment, the cells were 
exposed to cisplatin and pemetrexed for 6 h and washed 
out with drug‑free medium, followed by 96 h of recovery 
(96 h‑post wo).
Flow cytometry. Untreated cells, and those at 96‑h post wo 
and 21 days post‑treatment washout (21 days‑post wo) were 
collected and fixed with ice‑cold 70% ethanol. The cells at 21 
days‑post wo were allowed to recover by replacement of the 
fresh medium 3 times/week. No split was carried out, in order 
to permit the RAL cells to form resistant clones and repopu-
late the flask. Flow cytometric analysis was performed using 
a FACSCanto flow cytometer (BD Biosciences). Data acquisi-
tion and analysis were performed using FACSDiva software 
(Version 6.1.3, BD Biosciences). Samples were run in triplicate 
(10,000 events for each replica). Data report the mean value of 
3 experiments with standard deviations <5%.
TUNEL assay. Cells were fixed in 1% paraformaldehyde in 
phosphate‑buffered saline (PBS) on ice for 15 min, suspended 
in cold ethanol (70%) and stored overnight at ‑20˚C. The 
cells were then washed twice in PBS, resuspended in PBS 
containing 0.1% Triton X‑100 for 5 min at 4˚C, incubated in 
50 µl of solution containing TdT and FITC‑conjugated dUTP 
deoxynucleotides 1:1 (Roche Diagnostics GmbH) in a humidi-
fied atmosphere for 90 min at 37˚C in the dark, washed in 
PBS, counterstained with propidium iodide (PI, 200 µg/ml, 
MP Biomedicals) and RNase (10,000 U/ml, Sigma‑Aldrich; 
Merck KGaA) for 30 min at 4˚C in the dark, and analyzed by 
flow cytometry.
Cell cycle distribution analysis. The cells were fixed in 
ethanol (70%) and stained in a solution containing 100 µg/ml 
of PI (Sigma‑Aldrich; Merck KGaA), 10,000 U/ml of RNase 
(Sigma‑Aldrich; Merck KGaA) and 0.01% NP40 (Sigma‑Aldrich; 
Merck KGaA). After 24 h, the samples were analyzed by flow 
cytometry. Data were elaborated using ModFit (DNA Modelling 
System) software (Version 4.1.7, Verity Software House Inc.), 
and expressed as fractions of cells in the different cell cycle 
phases.
Annexin V assay. The cells were washed once in PBS, 
incubated with 250 µl of Annexin V‑FITC in binding buffer 
(eBioscience) for 15 min at 37˚C in a humidified atmosphere 
in the dark, and then washed in PBS and suspended in binding 
buffer. Immediately before flow cytometric analysis, PI 
was added to a final concentration of 5 µg/ml to distinguish 
between total apoptotic cells (Annexin V+ and PI- or PI+) and 
necrotic cells (Annexin V- and PI+).
siRNA transfection. CDKN1A Silencer Select Validated siRNA 
(Thermo Fisher Scientific, Inc.) and a validated Negative 
Universal Control™ (Invitrogen; Thermo Fisher Scientific, 
Inc.) were used. The cells were seeded in 25 cm2‑flasks at a 
density of 2.5x105 cells. The transfections were carried out 
using the TransIT‑X2 Dynamic Delivery System (Mirus Bio 
LCC) and Opti‑MEM GlutaMax medium (Invitrogen; Thermo 
Fisher Scientific, Inc.) without antibiotics. siRNA/TransIT‑X2 
was incubated with the cells for 25 min. The total incubation 
time before the combinational treatment was 24 h.
Cellular fractionation, protein extraction and western blot 
analysis. Cells (7x106) that had either been treated with 
cisplatin and pemetrexed or under the control condition were 
washed in hypotonic buffer (10 mM Tris, 5 mM MgCl2). Triton 
X‑100 (10% stock) was added to a 0.3% final concentration. 
The suspension was passed twice through a 22‑gauge needle 
with a syringe and centrifuged at 800 x g for 10 min at 4˚C to 
remove debris. The supernatant was collected. Protease/phos-
phatase inhibitor cocktail (Sigma‑Aldrich; Merck KGaA) was 
added and protein lysate was saved as the cytosolic fraction. 
Nuclei were isolated following 2 subsequent centrifugations at 
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800 x g for 10 min at 4˚C and lysed in RIPA buffer containing 
1 µg/ml of DNAse (Voden Medical Instruments). Western blot 
analysis was performed as previously described (16). The list 
of the specific antibodies and conditions used is available upon 
request.
RNA extraction, purification and reverse transcription. 
Total RNA was extracted using TRIzol® reagent (Invitrogen; 
Thermo Fisher Scientific, Inc.) and purified with the RNeasy 
MinElute Cleanup kit (Qiagen GmbH) according to the 
manufacturer's instructions. DNase enzyme digestion (Qiagen 
GmbH), was performed to exclude genomic DNA contamina-
tion. Purified RNA was eluted with 14 µl of RNase‑free water 
(Qiagen GmbH). A total of 500 ng of purified RNA were 
reverse transcribed into cDNA using the RT2 First Strand kit 
(SABiosciences Corp.) in a volume of 20 µl reaction and diluted 
with 91 µl of nuclease‑free water, following the manufacturer's 
instructions.
RT2 Profiler™ PCR array and quantitative (real‑time) PCR 
(qPCR). The Human Oncogenes and Tumor Suppressor genes 
RT2 Profiler™ PCR Array (complete list of genes is presented 
in Table SI) was used to profile the expression of 84 different 
key genes that promote oncogenesis. A mix containing 102 µl 
of cDNA, 1,248 µl of water and 1,350 µl of 2X RT2 SYBR 
Green Master Mix (SABiosciences Corp.) was prepared and 
25 µl were added to each well. qPCR was performed using 
the Real‑Time Cycler 7500 (Applied Biosystems) with the 
following thermal profile: 95˚C for 10 min; 40 cycles: 95˚C 
for 15 sec and 60˚C for 1 min; dissociation curve at 95˚C 
for 1 min, 55˚C 30 sec and 95˚C for 30 sec. Raw data from 
qPCR were exported and analyzed using online software at 
the GeneGlobe Data Analysis Center website (Qiagen GmbH). 
Fold changes in gene expression were calculated using the 
2-ΔΔCq method (17).
Differentially expressed genes (with >2‑fold changes in 
expression) were validated with 3 biological independent repli-
cates by RT‑qPCR (Table SIIA), using 1 µl of cDNA, 0.4 µM 
of specific primers, 12.5 µl of RT2 SYBR‑Green Master Mix 
and water up to a final volume of 25 µl. The relative gene 
expression was calculated as previously mentioned.
A protein‑protein interaction (PPI) network and func-
tional module were established using the Search Tool for the 
Retrieval of Interacting Genes (STRING) (18). A confidence 
score of ≥0.4 and a maximum number of interactors of (=) 0 
were set as the cut‑off criteria.
Bisulfite sequencing. CDKN1A and RASSF1 gene promoter 
methylation was analyzed by bisulfite sequencing (BS). A 
total of 1 µg of genomic DNA was bisulfite‑treated using the 
EZ DNA Methylation Kit (Zymo Research), which induces 
the chemical conversion of unmethylated cytosine to uracil, 
and eluted in 20 µl of elution buffer. A total of 3 µl of bisul-
fite‑treated DNA were amplified by PCR in a total volume of 
20 µl, with 4 mM of MgCl2, 0.5 mM of each dNTP, 0.2 µM 
of each primer, and 0.5 unit of Taq Hot Start Thermostable 
DNA polymerase (EuroClone). The primers were designed 
using the Methyl Primer Express® Software v1.0 (Applied 
Biosystems) and their sequences are presented in Table SIIB. 
Amplifications were performed using the following thermal 
profile: 95˚C for 2 min followed by 38 cycles at 95˚C for 30 sec, 
59˚C for 30 sec and 72˚C for 30 sec. The PCR products were 
purified from agarose gel using the EuroGold Gel Extraction 
kit (EuroClone) and cloned using the pGEM‑T Easy Vector 
System (Promega Corp.) following the manufacturer's instruc-
tions. In total, 10 white colonies for each time point were 
resuspended in 50 µl of water and tested by colony PCR using 
the same PCR conditions as before, adding an extra step at 
95˚C for 10 min to induce cell lysis. PCR products were then 
purified by QIAquick PCR Purification kit (Qiagen GmbH). 
Sequencing of PCR products was performed using the Big 
Dye Terminator Cycle Sequencing kit (Applied Biosystems) 
on the Applied Biosystems 3130 Avant Genetic Sequencer.
Chromatin immunoprecipitation (ChIP). ChIP assay was 
performed as previously described (19). Washes of immuno-
precipitated (IP) samples were carried out for 1 min using the 
HulaMixer® Sample Mixer (Thermo Fisher Scientific, Inc.), 
setting the rotation as follows: Orbital (rpm) 58‑1, Reciprocal 
(deg) 13˚‑01, Vibro (pause) 5˚ off. IP purified DNA and inputs 
were amplified using genomic primer sets specific for RASSF1 
and CDKN1A gene promoters designed to overlap the regions 
investigated by BS (Table SIIB). RT‑qPCR was performed in a 
total volume of 20 µl including 5 µl of IP‑DNA, 0.1 µM of each 
primer and 14 µl of SsoAdvanced™ Universal SYBR®-Green 
Supermix (Bio‑Rad Laboratories, Inc.). Amplification was 
carried out in the CFX Connect™ Real‑Time PCR Detection 
System (Bio‑Rad Laboratories, Inc.) using a two‑step protocol 
consisting of 95˚C for 3 min, 95˚C for 10 sec and 64˚C for 
30 sec, 40 cycles, followed by a melting curve step to confirm 
the specificity of the PCR products. ChIP data were analyzed 
using the Percent Input Method: input Ct values corresponding 
to 1% of initial chromatin were adjusted to 100% and used to 
normalized Ct values of IP‑DNA samples.
Immunocytochemistry (ICC). Cell blocks were prepared by 
fixing untreated cells, and cells at 96‑h post wo and 21 days‑ post 
wo in 10% neutral‑buffered formalin for 24 h and then embed-
ding them in paraffin using Bio Agar gel (Bio Optica). Sections 
4‑µm‑thick were cut and placed on positive‑charged slides (Bio 
Optica). Immunostaining was performed with the Ventana 
Benchmark XT system (Ventana Medical Systems, Tucson, 
AZ) and the Optiview DAB Detection kit (Ventana Medical 
Systems), an indirect, biotin‑free system for mouse IgG, mouse 
IgM and rabbit primary antibodies detection. The kit aims to 
identify targets by immunohistochemistry (IHC) and ICC in 
formalin‑fixed, paraffin‑embedded sections that are stained on 
the Ventana automated slide stainers and visualized by light 
microscopy. Incubation time and temperature are set by the 
stainer automatically. Antibodies against CDKN1A (DCS‑60.2, 
Cell Marque, Ventana Medical Systems), thymidylate synthase 
(TS; clone 4H4B1, Life Technologies; Thermo Fisher Scientific, 
Inc.) and the DNA excision repair cross‑complementation group 
1 (ERCC1; clone 8F1, Neomarkers) were used. The CDKN1A 
antibody was pre‑diluted by the supplier and incubated at 
room temperature for 16 min. For TS and ERCC1 detection, 
antibodies diluted at 1:300 and 1:100 were used, respectively, 
and incubated at room temperature for 32 min. Sections 
were automatically counterstained at room temperature for 
16 min with hematoxylin II (Ventana Medical Systems). 
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Hematoxylin and eosin staining, at room temperature for 16 
and 1 min respectively, was also performed for each sample. 
Biomarker expression was semi‑quantitatively analyzed as 
the percentage of immunopositive tumor cells out of the total 
number of tumor cells. All samples were evaluated by a trained 
pathologist and analyzed using an upright light microscope in 
bright field (Axioscope, Zeiss).
Statistical analysis. Three biological replicates for each 
time‑point (untreated cells, and cells at 96 h‑post wo and 
21 days‑post wo) were analyzed for each experiment and the 
results were reported as the mean values and standard devia-
tion (SD) or standard error (SEM). Time points were compared 
using the non‑parametric Friedman's test followed by the 
Bonferroni post‑hoc test. Reported P‑values were two‑sided and 
P<0.05 was used as the threshold for significance. Correction 
for multiple testing was not performed due to the explorative 
aim of this analysis. Statistical analyses were carried out using 
STATA/MP 15.0 for Windows (Stata Corp. LP).
Results
Cytotoxic effect analysis. The anti‑proliferative effects of 
cisplatin and pemetrexed used as single agents or in combina-
tion were evaluated using the RAL cells by MTS assay at 24, 
48, 72 and 96 h after drug washout. The RAL cells exhibited 
no or only slight sensitivity to pemetrexed and cisplatin, with 
100 and 71% of cell survival at 96 h, respectively. Although a 
higher cytotoxic effect was observed at the end of the exposure 
time to both drugs, the half‑maximal inhibitory concentra-
tion (IC50) value was never reached (64% of cell survival at 
96 h‑post wo) (Fig. 1A).
TUNEL assay (Fig. 1B) revealed a percentage of apoptotic 
cells consistent with that of non‑surviving cells detected by 
MTS assay when the two drugs were used in combination. In 
particular, a significant increase in the number of apoptotic 
cells was observed at 96 h‑post wo (44.6%, P=0.002). Notably, 
the cells had fully recovered 21 days after the end of treatment 
and began to grow and divide normally. Cell cycle distribution 
analysis (Fig. 1C) revealed a significant decrease in the number 
of cells in the G0G1 phase (1.7%) and a marked increase in 
the number of cells in the G2M phase at 96 h‑post wo (76%), 
whereas no differences with respect to the untreated samples 
were detected in the cells in the S phase. These cell cycle 
perturbations had fully recovered at 21 days‑post wo when 
the cell percentages in the G0G1 or G2M phase were similar 
to those of the untreated cells (56.7% vs. 56.5%, and 18.2% vs. 
17.1%, respectively).
Gene expression analysis. The expression of 84 oncogenes and 
tumor suppressor genes (TSGs) was analyzed in the untreated 
cells, and in the cells at 96 h‑post wo and 21 days‑post wo. In 
total, 11/84 genes were not expressed (ESR1, FOXD3, HGF, 
KIT, MOS, MYCN, ROS1, RUNX3, TNF, TP73 and WT1) 
and 2/84 were unevaluable (BCL2 and WWOX). Among the 
genes included in the panel, 8 (CDKN1A, CDKN3, EGF, FHIT, 
JAK2, MYC, RASSF1 and RB1) and 3 (CDKN1A, CDKN3 and 
RASSF1) were differentially expressed by >2‑fold in the cells at 
96 h‑post wo and 21 days‑post wo, respectively (Fig. 2A and B). 
In particular, RT‑qPCR analysis of the cells at 96 h‑post wo 
confirmed that CDKN1A (P=0.002), EGF (P=0.001) and 
JAK2 (P=0.009) were significantly upregulated with a >2 
fold change, whereas FHIT was downregulated (P=0.008). A 
significant increase in CDKN1A mRNA expression was also 
maintained and confirmed in the cells at 21 days‑post wo 
(P=0.011) (Fig. 2C). The STRING database used to visualize 
protein‑protein interaction (PPI) revealed a network with high 
degree of connectivity between the differentially expressed 
genes, KRAS and AKT, with a PPI enrichment P‑value equal 
to 0.00106 (Fig. S1).
Epigenetic modifications associated with the CDKN1A 
promoter region. Subsequently, it was investigated whether 
epigenetic modifications (DNA methylation and histone 
marks) are associated with gene expression, by performing BS 
and ChIP on the RAL cells at 96 h and 21 days following the 
combined treatment. The results for the CDKN1A gene were 
compared with those obtained for RASSF1, a tumor suppressor 
gene often silenced and hypermethylated in RAL cells (15). 
The promoter regions of CDKN1A and RASSF1 are shown in 
Fig. 3A and B, respectively.
DNA methylation analysis was performed by BS in 10 clones 
corresponding to the untreated cells, and cells at 96 h‑post wo 
and 21 days‑post wo. The methylation percentage of each cyto-
sine was calculated by the average of the methylation status 
of the 10 clones. The promoter region of the CDKN1A gene 
was completely unmethylated (data not shown), whereas the 
RASSF1 gene promoter exhibited a hypermethylated (>40%) 
Figure 1. Cytotoxic activity of cisplatin and pemetrexed in RAL cells. (A) Effect of cisplatin and pemetrexed used alone and in combination on cell survival 
evaluated by MTS assay at 24, 48, 72 and 96 h after drug washout. Plasma peak concentrations were used for both drugs. Mean values and SEM of 3 indepen-
dent experiments performed in octuplicate are reported. (B) Percentage of apoptotic cells evaluated by TUNEL assay in the cells at 96 h‑ and 21 days‑post wo. 
Mean values and SEM of 3 independent experiments are reported. (C) Cell cycle analysis 96 h‑ and 21 days‑post wo. Mean values and SEM of 3 independent 
experiments are reported. **P<0.01. post wo, post‑treatment washout.
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CpG island (Fig. 3C). No significant differences were detected 
among the treated and untreated cells.
Three post‑transcriptional histone modifications were 
investigated by ChIP assay: Two of these were associated 
with transcriptional active chromatin, i.e., the acetylated form 
of the H3 histone tail (acH3) and trimethyl‑Lysine 4 of H3 
histone tail (H3K4me3), and one enriched in transcriptional 
silenced chromatin domains, trimethyl‑Lysine 27 of H3 
histone tail (H3K27me3). The chromatin histone marks (acH3 
and H3K4me3) corresponding to a transcriptionally open 
chromatin region were ≥7‑fold enriched in the promoter region 
of the CDKN1A gene compared to RASSF1 (Fig. 3D and E). 
Conversely, the repressive histone mark H3K27me3 showed 
comparable results in the two genes (Fig. 3F). Isotype rabbit 
IgG was used as the background control (Fig. 3G). No 
substantial differences between the untreated cells and cells 
surviving the combination treatment were detected in histone 
modifications associated with the promoters of both genes, 
with the exception of a significant 4‑fold increase in acH3 
enrichment in the CDKN1A promoter detected in the cells at 
96 h‑post wo with respect to the untreated cells, and cells at 
21 days‑post wo (Fig. 3D).
Effects of cisplatin and pemetrexed on CDKN1A, TS and 
ERCC1 protein expression and subcellular localization. 
An upregulation of CDKN1A protein expression was found 
in the cells at 96 h‑post wo with respect to the controls 
(85 and 10% immunopositive cells, respectively), whereas 
CDKN1A expression in the cells at 21 days‑post wo was 
equal to baseline (5% immunopositive cells) (Fig. 4A). In 
particular, it was observed that 10% of cells at 96 h‑post 
wo exhibited a strong cytoplasmic expression (Fig. 5A) that 
was virtually absent in the untreated cells, and in cells at 
21 days‑post wo.
The results of western blot analysis of whole lysates 
(Fig. S2) were in line with the ICC results, confirming that 
Figure 2. Effect of cisplatin and pemetrexed on the expression of oncogenes and tumor suppressor genes in RAL cells. (A and B) Volcano plots of PCR array 
results in cells at 96 h‑post wo and 21 days‑post wo. The solid black line indicates a 1.0‑fold change in gene expression, while the dotted lines indicate the 
desired threshold of a 2.0‑fold change in gene expression. The horizontal line in bold indicates the desired 0.05 threshold for the P‑value of the ANOVA test. 
Blue, black and red spots indicate downregulated, unaltered and upregulated genes, respectively. (C) qPCR of significant genes resulted modulated by PCR 
array. The relative expression (fold change) of each gene was calculated using the 2-ΔΔCq method, assuming the expression of each gene in untreated cells as 1. 
Mean values and SEM of 3 independent experiments are reported. *P<0.05; **P<0.005; ***P<0.001 indicates significant differences in the cells at 96 h‑post wo 
and 21 days‑post wo compared to the untreated control cells. ^P<0.05; ^^P<0.005 indicates significant differences in the cells at 96 h‑post wo compared those 
at 21 days‑post wo. post wo, post‑treatment washout.
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the cells at 96 h‑post wo exhibited a marked upregulation of 
CDKN1A protein expression, while in the cells at 21 d‑post 
wo, the protein level decreased with respect to the cells at 
96 h‑post wo.
Moreover, western blot analysis of protein lysates from 
subcellular compartments revealed that CDKN1A overex-
pression observed following treatment was mainly related 
to a protein increment in the cytoplasmic fraction. Again, 
the increased CDKN1A expression was more evident in the 
cytoplasm of the cells at 96 h‑post wo (Fig. 5B).
We also characterized the RAL cells for the expression of 
TS and ERCC1, known to be potential markers of response 
to pemetrexed and cisplatin, respectively. The RAL cells 
exhibited a high basal nuclear and cytoplasmic expression 
of TS, 80% of which were strongly immunopositive. Strong 
TS stain intensity was also observed in the cytoplasm 
(Fig. 4B). An additional upregulation of cytoplasmic TS 
was observed in the cells at 96 h‑post wo, whereas only 
40% of the cells were immunopositive at 21d‑post wo. As 
regards ERCC1 protein expression, almost 100% of the 
untreated cells and cells at 96 h‑post wo were strongly 
positive, whereas the cells at 21 days‑post wo exhibited 
a somewhat lower positivity (75%) (Fig. 4C). The TS and 
ERCC1 protein expression levels were also confirmed by 
western blot analysis (Fig. S2). In all the immunocyto-
chemical evaluations, the cells at 96 h‑post wo appeared 
Figure 3. Effect of cisplatin and pemetrexed on epigenetic modifications associated with CDKN1A and RASSF1 gene promoters. CpG island report of 
(A) CDKN1A and (B) RASSF1 promoter regions. Each vertical bar represents a CpG site. The regions amplified by the primer sets are indicated by arrows. 
Bisulfite sequencing (BS) primers were designed to overlap the 5' region close to the transcription start site (+1). ChIP primers were designed to be included 
in the region analyzed by BS. (C) Percentage of DNA methylation of RASSF1 promoter detected by BS analysis (CDKN1A gene promoter was completely 
unmethylated and thus not included). (D‑G) ChIP analysis of histone modifications associated with CDKN1A and RASSF1 promoter regions. Data are relative 
to immunoprecipitated DNA obtained with antibodies recognizing (D) acetylated lysines of H3 histone tail, (E) trimethylated‑Lysine 4 of H3 histone tail 
(H3K4me3) and (F) trimethylated‑Lysine 27 of H3 histone tail (H3K27me3). (G) Rabbit IgG was used as background control. Chromatin from untreated RAL 
cells was compared with chromatin from cells at 96 h‑ and 21 days‑post wo RAL cells. Ct values were normalized to inputs and reported as mean value and 
SEM of 3 independent experiments. *P<0.05. post wo, post‑treatment washout.
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larger than their untreated counterparts, according to the 
well‑known acute effects of cisplatin treatment (20,21).
Promotion of cell death by CDKN1A knockdown in the cells 
treated with the cisplatin‑pemetrexed treatment combination. 
The role of CDKN1A gene in the cellular response to cisplatin 
and pemetrexed was investigated by transient silencing. The 
CDKN1A mRNA levels decreased significantly with respect 
to those observed in cells transfected with an appropriate 
negative control (scrambled oligonucleotide), confirming 
CDKN1A knockdown by siRNA. Moreover, its protein level 
was undetectable in cells transfected with CDKN1A siRNA 
(Fig. S3).
The RAL cells in which CDKN1A was silenced and which 
were exposed to the cisplatin‑pemetrexed combination and 
evaluated 96 h after washout exhibited a consistently significant 
increase in cell death compared to the scramble control‑trans-
fected cells at 96 h‑post wo. TUNEL assay revealed that there 
were 73.6% of apoptotic cells when CDKN1A was knocked 
down compared with 44% of apoptotic cells in the untreated 
cells transfected with CDKN1A siRNA (Figs. 6A and S4). As 
was expected, when scramble RNA was used instead of the 
CDKN1A siRNA probes, the cisplatin‑pemetrexed combina-
tion induced a considerable increase in cell death compared to 
the untreated control conditions (40.1% vs. 22.1%, respectively) 
(Fig. 6A). The increase in cell death detected by TUNEL assay 
in the cells at 96 h‑post wo with CDKN1A silencing was also 
confirmed by Annexin V assay, which identified both early 
and late apoptosis. In the 96 h‑post wo condition, CDKN1A 
silencing was associated with 51.9% of cells in early apoptosis 
compared with 23.2% cells in the untreated siRNA counter-
parts and 9.4% in the cells at 96 h‑post wo transfected with the 
scramble control (Figs. 6B and S4).
Finally, a cell cycle distribution analysis revealed that 
the cisplatin‑pemetrexed combination led to a significant G2 
phase block (Figs. 6C and S4) that was more evident in the 
cells at 96 h‑post wo than in the untreated cells transfected 
with either CDKN1A siRNA (58.6% in 96 h‑post wo vs. 10.9% 
in untreated cells) or scramble RNA (56% in 96 h‑post wo vs. 
18.2% in untreated cells). Furthermore, as CDKN1A inhibits 
the activity of cyclin‑CDK2, ‑CDK1 and ‑CDK4/6 complexes, 
functioning as a regulator of cell cycle progression during G1 
and S phases, a significant increase in the cells in the G1‑phase 
was also detectable in the cells transfected with siRNA at 
96 h‑post wo with respect to their scramble control counter-
parts (11.7 and 2.4%, respectively). No significant differences 
in percentages of S phase cells were detected in the untreated 
cells. Treatment with the cisplatin‑pemetrexed combination 
caused an increase in the number of cells in the S phase 
(41.6% vs. 28.3% in the cells at 96 h‑post wo and untreated 
cells, respectively). When CDKN1A was knocked down, the 
percentage of cells in the S phase decreased to the level of the 
untreated cells (29.7%).
Discussion
Platinum‑based regimens used in combination with other 
chemotherapeutic compounds, such as pemetrexed, are still 
the optimal treatment selection for the adjuvant treatment of 
NSCLC and as the first‑line therapy of advanced disease in 
patients whose tumor molecular signature limits the useful-
ness of biological therapies (22). However, the majority of 
patients are susceptible to disease progression due to acquired 
resistance.
The aim of the present study was to identify novel 
biomarkers of sensitivity/resistance to the cisplatin‑peme-
trexed treatment combination using the RAL cell line, an 
in vitro model representative of a subset of NSCLC patients 
who cannot benefit from biological therapies. The data of 
the present study revealed a significant increase in antitumor 
activity when both drugs were used in combination, rather 
than as single agents. For this reason, the present study aimed 
Figure 4. Effect of cisplatin and pemetrexed on protein expression of CDKN1A, TS and ERCC1 in RAL cells. Representative immunocytochemical staining 
for (A) CDKN1A, (B) TS and (C) ERCC1 in untreated cells, at 96 h‑post wo and 21 days‑post wo; x40 magnification. post wo, post‑treatment washout; TS, 
thymidylate synthase; ERCC1, DNA excision repair cross‑complementation group 1.
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to perform a more in depth investigation of the combination of 
the two drugs, with no further investigations on single drugs. 
The observed antitumor activity was transient and 21 days 
after the treatment washout, the RAL cells had fully resumed 
their proliferation capacity.
Firstly, TS and ERCC1 protein expression was analyzed, 
since it is known that these markers may play a role in the 
response to pemetrexed and cisplatin respectively, even 
though contradictory results have been observed (23‑27). In 
the present study, both markers were highly expressed either 
in the untreated cells and in the cells at 96 h‑post wo, thus 
confirming their limited utility as response markers in this cell 
line.
Subsequently, the expression of genes involved in different 
biological pathways was analyzed to identify the genes impli-
cated in the resistance of RAL cells to the cisplatin‑pemetrexed 
treatment.
To this purpose, the gene profiling of 84 TSGs and onco-
genes was performed followed by the validation of altered 
gene expression by qPCR. Among the genes confirmed as 
differentially expressed in the cells at 96 h‑post wo, FHIT was 
the only one downregulated, perhaps contributing to platinum 
drug resistance via the serine threonine kinase AKT, particu-
larly in TP53‑mutated patients (28‑30). The CDKN1A, EGF 
and JAK2 mRNA expression levels were >2‑fold higher in the 
cells at 96 h‑post wo compared to the untreated cells. Both 
EGF and JAK2 are upstream regulators of STAT3 activity. 
STAT3 acts as a transcription factor, inducing the expression 
of genes involved in cancer progression, apoptosis resistance, 
cell proliferation and sustained angiogenesis (31). The signifi-
cant overexpression of EGF and JAK2 genes suggests that the 
activation of the JAK2/STAT3 signaling pathway may play a 
role in the resistance to chemotherapy observed in the model 
in the present study, as reported elsewhere (32).
Figure 6. Effect of CDKN1A knockdown on cytotoxic activity of the cisplatin and pemetrexed combination in RAL cells. (A) Percentage of apoptotic cells 
evaluated by TUNEL assay in cells at 96 h‑post wo with respect to untreated cells transfected with either scramble (scr) or CDKN1A siRNA. (B) Evaluation 
by Annexin‑V assay of the percentage of apoptotic (early or late) cells in untreated and 96 h‑post wo cells transfected with either scramble (scr) or CDKN1A 
siRNA. (C) Cell cycle analysis in untreated cells and cells at 96 h‑post wo transfected with either scramble (scr) or CDKN1A siRNA. Mean values and SEM 
of 3 independent experiments are reported. *P<0.05; **P<0.01; ***P<0.001. n.s., not significant, post wo, post‑treatment washout.
Figure 5. Effect of cisplatin and pemetrexed on CDKN1A expression and its cellular localization. (A) Representative hematoxylin and eosin staining (left 
panel) and CDKN1A staining (right panel) of cells at 96 h‑post wo; x40 magnification. (B) Representative western blot of the CDKN1A expression level in 
cytoplasmic and nuclear protein fractions of untreated cells and cells at 96 h‑post wo. Lamin B and α‑tubulin were used as loading controls of the nuclear and 
cytoplasmic fractions, respectively. post wo, post‑treatment washout.
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Since it was the most upregulated gene in the cells 
at 96 h‑post wo and the only gene still upregulated at 21 
d‑post wo, the role of CDKN1A was further investigated. 
The CDKN1A gene plays a crucial role in DNA repair, cell 
differentiation and apoptosis through the regulation of the cell 
cycle. It blocks DNA replication by binding to proliferating 
cell nuclear antigen and inhibits the activity of cyclin‑CDK4 
or ‑CDK2 complexes. As a result, the cell cycle is arrested in 
the G1/S or G2/M transitions (33,34). The role of CDKN1A in 
apoptosis is multifaceted and remains unclear (35‑37). Some 
studies have suggested that it may mediate cell cycle arrest 
following DNA damage in either a p53‑dependent or ‑inde-
pendent manner, leading to an increase in apoptosis (38,39). 
Others have found that the inhibition of cell cycle progression, 
associated with elevated levels of CDKN1A gene expression, 
prevents apoptosis (34,40). Such a positive or a negative influ-
ence on cell growth and survival may result from its subcellular 
localization (34,41). Its cytoplasmic localization may favor cell 
proliferation as it acts as a chaperone for cyclin E, particularly 
when p53 is damaged or absent (42). Conversely, CDKN1A 
nuclear localization is associated with its better known func-
tion of modulator of cell cycle arrest and negative regulator of 
DNA repair pathways, resulting in unresolved DNA damage 
and growth inhibition (36).
Shoji et al reported that CDKN1A expression, in a large 
fraction of patients with completely resected pathologic 
stage I‑IIIA NSCLC, was associated with a favorable prog-
nosis (43). Moreover, a number of studies have demonstrated 
that CDKN1A modulation is involved in the response to 
different therapies in many cancer types (44‑51). For example, 
cytoplasmic CDKN1A localization in testicular embryonal 
carcinoma leads to cisplatin resistance. In particular, high cyto-
plasmic CDKN1A levels exert a protective effect against 
cisplatin in embryonal carcinoma cell lines (52). The present 
study demonstrated that only 10% of the untreated RAL cells 
expressed CDKN1A, in line with the weak positive expres-
sion reported by Rosetti et al (46). The cytoplasmic expression 
revealed by western blot analysis (Fig. 5B) in untreated cells 
could be linked to its oncogenic activity in such an aggressive 
cell line, which is metastasis‑derived.
In the present study, a significant CDKN1A upregulation 
was detected in the cells at 96 h‑post wo, both at the mRNA 
and protein level, having a 10‑fold higher mRNA expres-
sion and a marked cytosolic CDKN1A upregulation with 
respect to the untreated cells. In the cells at 21 d‑post wo, 
CDKN1A remained upregulated, even though at a lower extent 
(Figs. 2C and S2).
Chromatin accessibility to transcriptional machinery is a 
crucial regulator of gene expression known to be involved in 
the clinical course of lung cancer (53). The analysis of epigen-
etic modifications associated with the CDKN1A gene promoter 
revealed that its gene expression regulation was not mediated 
by DNA methylation, but rather by chromatin histone marks 
H3K4me3 and acH3, representative of a transcriptionally open 
and active chromatin structure (Fig. 3). Although the increased 
level of association of acH3 in the promoter region of CDKN1A 
in 96 h‑post wo cells compared to untreated cells correlated 
with increased gene expression, it was not sufficient to confirm 
epigenetics as the main molecular mechanism involved in the 
modulation of CDKN1A gene expression.
Taking into account the subcellular localization 
of CDKN1A in RAL cells surviving the combined 
chemotherapeutic action of cisplatin and pemetrexed, 
the high cytoplasmic expression levels of the protein 
appear consistent with the observed reduction in drug 
efficacy. It has been demonstrated that the phosphorylation 
of CDKN1A and its translocation to the cytosol, with 
the consequent progression of cell cycle through G1/S 
phase (54) and activation of anti‑apoptotic pathways, may be 
AKT‑mediated (55) and interfere with the cytotoxic effect 
of chemotherapeutic drugs (54‑59). Preclinical and clinical 
data have also highlighted that PI3K/AKT/mTOR pathway 
inhibitors may be used in combination with other agents for 
the treatment of NSCLC (60).
In the present study, it was demonstrated that in the 
NSCLC cell line harboring KRAS G12C and TP53 G244C 
mutations, CDKN1A silencing increased apoptosis and 
G1/S cell cycle arrest, thus increasing the efficacy of the 
cisplatin‑pemetrexed combination. These findings support the 
hypothesis that CDKN1A functions as an oncogene, promoting 
cancer cell proliferation by inhibiting apoptosis, and highlight 
its potential role as a therapeutic response indicator of the 
pemetrexed‑cisplatin combination in NSCLC.
A retrospective study to evaluate CDKN1A gene expres-
sion and localization in association with patient response to 
standard chemotherapy could also confirm CDKN1A role as 
a predictive biomarker of response to therapy in KRAS‑ and 
TP53‑mutated NSCLC.
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